1-13 of 13
Seungwon Kim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit

Marco A. Mascarella, Tolani F. Olonisakin, Purva Rumde, Varun Vendra, Melonie A. Nance, Seungwon Kim, Mark W. Kubik, Shaum S. Sridharan, Robert L. Ferris, Moon J. Fenton, Daniel R. Clayburgh, James P. Ohr, Sonali C. Joyce, Malabika Sen, James G. Herman, Jennifer R. Grandis, Dan P. Zandberg, Umamaheswar Duvvuri
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 723–730.
https://doi.org/10.1158/1078-0432.CCR-22-1768
Published: 16 February 2023
View article titled, Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit
Open the PDF for Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer

Robert L. Ferris, Jessica Moskovitz, Sheryl Kunning, Ayana T. Ruffin, Carly Reeder, James Ohr, William E. Gooding, Seungwon Kim, Brian J. Karlovits, Dario A.A. Vignali, Umamaheswar Duvvuri, Jonas T. Johnson, Daniel Petro, Dwight E. Heron, David A. Clump, Tullia C. Bruno, Julie E. Bauman
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1335–1344.
https://doi.org/10.1158/1078-0432.CCR-21-0426
Published: 01 April 2022
View article titled, Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer
Open the PDF for Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer in another window
Journal Articles

Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients

Umamaheswar Duvvuri, Jonathan George, Seungwon Kim, Diego Alvarado, Veronique M. Neumeister, Ahmed Chenna, Richard Gedrich, Thomas Hawthorne, Theresa LaVallee, Jennifer R. Grandis, Julie E. Bauman
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (19): 5752–5758.
https://doi.org/10.1158/1078-0432.CCR-18-3453
Published: 01 October 2019
View article titled, Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients
Open the PDF for Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients in another window
Includes: Supplementary data
Journal Articles

Editor's Note: Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer

Bradley A. Schiff, Andrea B. McMurphy, Samar A. Jasser, Maher N. Younes, Dao Doan, Orhan G. Yigitbasi, Seungwon Kim, Ge Zhou, Mahitosh Mandal, Benjamin N. Bekele, F. Christopher Holsinger, Steven I. Sherman, Sai-Ching Yeung, Adel K. El-Naggar, Jeffrey N. Myers
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4862.
https://doi.org/10.1158/1078-0432.CCR-19-2052
Published: 01 August 2019
View article titled, Editor's Note: Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer
Open the PDF for Editor's Note: Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer in another window
Journal Articles

Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals

Gulidanna Shayan, Benjamin A. Kansy, Sandra P. Gibson, Raghvendra M. Srivastava, James Kyle Bryan, Julie E. Bauman, James Ohr, Seungwon Kim, Umamaheswar Duvvuri, David A. Clump, Dwight E. Heron, Jonas T. Johnson, Robert M. Hershberg, Robert L. Ferris
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (1): 62–72.
https://doi.org/10.1158/1078-0432.CCR-17-0357
Published: 02 January 2018
View article titled, Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals
Open the PDF for Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals in another window
Includes: Supplementary data
Journal Articles

Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer

Neil D. Gross, Julie E. Bauman, William E. Gooding, William Denq, Sufi M. Thomas, Lin Wang, Simion Chiosea, Brian L. Hood, Melanie S. Flint, Mai Sun, Thomas P. Conrads, Robert L. Ferris, Jonas T. Johnson, Seungwon Kim, Athanassios Argiris, Lori Wirth, Marina N. Nikiforova, Jill M. Siegfried, Jennifer R. Grandis
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (12): 3289–3298.
https://doi.org/10.1158/1078-0432.CCR-13-3360
Published: 12 June 2014
View article titled, Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
Open the PDF for Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Predictive Biomarkers to Anti-VEGF Therapy: Progress toward an Elusive Goal

Rekha Gyanchandani, Seungwon Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (4): 755–757.
https://doi.org/10.1158/1078-0432.CCR-12-3585
Published: 14 February 2013
View article titled, Predictive Biomarkers to Anti-VEGF Therapy: Progress toward an Elusive Goal
Open the PDF for Predictive Biomarkers to Anti-VEGF Therapy: Progress toward an Elusive Goal in another window
Journal Articles

The Tyrosine Kinase Inhibitor, AZD2171, Inhibits Vascular Endothelial Growth Factor Receptor Signaling and Growth of Anaplastic Thyroid Cancer in an Orthotopic Nude Mouse Model

Fernando Gomez-Rivera, Alfredo A. Santillan-Gomez, Maher N. Younes, Seungwon Kim, David Fooshee, Mei Zhao, Samar A. Jasser, Jeffrey N. Myers
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (15): 4519–4527.
https://doi.org/10.1158/1078-0432.CCR-06-2636
Published: 01 August 2007
View article titled, The Tyrosine Kinase Inhibitor, AZD2171, Inhibits Vascular Endothelial Growth Factor Receptor Signaling and Growth of Anaplastic Thyroid Cancer in an Orthotopic Nude Mouse Model
Open the PDF for The Tyrosine Kinase Inhibitor, AZD2171, Inhibits Vascular Endothelial Growth Factor Receptor Signaling and Growth of Anaplastic Thyroid Cancer in an Orthotopic Nude Mouse Model in another window
Journal Articles

Growth-Inhibitory Effects of Human Anti-Insulin-Like Growth Factor-I Receptor Antibody (A12) in an Orthotopic Nude Mouse Model of Anaplastic Thyroid Carcinoma

Zhuoying Wang, Geetika Chakravarty, Seungwon Kim, Yasemin D. Yazici, Maher N. Younes, Samar A. Jasser, Alfredo A. Santillan, Corazon D. Bucana, Adel K. El-Naggar, Jeffrey N. Myers
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (15): 4755–4765.
https://doi.org/10.1158/1078-0432.CCR-05-2691
Published: 09 August 2006
View article titled, Growth-Inhibitory Effects of Human Anti-Insulin-Like Growth Factor-I Receptor Antibody (A12) in an Orthotopic Nude Mouse Model of Anaplastic Thyroid Carcinoma
Open the PDF for Growth-Inhibitory Effects of Human Anti-Insulin-Like Growth Factor-I Receptor Antibody (A12) in an Orthotopic Nude Mouse Model of Anaplastic Thyroid Carcinoma in another window
Journal Articles

Dual Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Inhibition with NVP-AEE788 for the Treatment of Aggressive Follicular Thyroid Cancer

Maher N. Younes, Yasemin D. Yazici, Seungwon Kim, Samar A. Jasser, Adel K. El-Naggar, Jeffrey N. Myers
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (11): 3425–3434.
https://doi.org/10.1158/1078-0432.CCR-06-0793
Published: 01 June 2006
View article titled, Dual Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Inhibition with NVP-AEE788 for the Treatment of Aggressive Follicular Thyroid Cancer
Open the PDF for Dual Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Inhibition with NVP-AEE788 for the Treatment of Aggressive Follicular Thyroid Cancer in another window
Journal Articles

Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice

Seungwon Kim, Christopher N. Prichard, Maher N. Younes, Yasemin D. Yazici, Samar A. Jasser, B. Nebiyou Bekele, Jeffrey N. Myers
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (2): 600–607.
https://doi.org/10.1158/1078-0432.CCR-05-1325
Published: 20 January 2006
View article titled, Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice
Open the PDF for Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice in another window
Journal Articles

An Orthotopic Model of Anaplastic Thyroid Carcinoma in Athymic Nude Mice

Seungwon Kim, Young-Wook Park, Bradley A. Schiff, Dao D. Doan, Yasemin Yazici, Samar A. Jasser, Maher Younes, Mahitosh Mandal, Benjamin N. Bekele, Jeffrey N. Myers
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (5): 1713–1721.
https://doi.org/10.1158/1078-0432.CCR-04-1908
Published: 08 March 2005
View article titled, An Orthotopic Model of Anaplastic Thyroid Carcinoma in Athymic Nude Mice
Open the PDF for An Orthotopic Model of Anaplastic Thyroid Carcinoma in Athymic Nude Mice in another window
Journal Articles

Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer

Bradley A. Schiff, Andrea B. McMurphy, Samar A. Jasser, Maher N. Younes, Dao Doan, Orhan G. Yigitbasi, Seungwon Kim, Ge Zhou, Mahitosh Mandal, Benjamin N. Bekele, F. Christopher Holsinger, Steven I. Sherman, Sai-Ching Yeung, Adel K. El-Naggar, Jeffrey N. Myers
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (24): 8594–8602.
https://doi.org/10.1158/1078-0432.CCR-04-0690
Published: 28 December 2004
View article titled, Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer
Open the PDF for Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer in another window